We start English website service. Thank you for waiting this.
Therapeutic vaccine for the chronic hepatitis B patients and carriers
Therapeutic vaccine should activate the patient’s immune system effectively to fight and control the virus infection.
CVI-HBV-002 formulated with highly immunogenic L-HBsAg and powerful adjuvant L-pampo is designed to overcome the immune tolerance status of the chronic hepatitis patients.
Efficacy of CVI-HBV-002 as a therapthe immune tolerance status of the chronic hepatitis patientseutic vaccine was examined using HBsAg/HLA-A2 Tg mouse model. Immune response was induced under the immune tolerance status and HBsAg particles in the blood were decreased by the antibody induced. Study results published in Clinical Vaccine and Immunology (2012).
Clinical trial is on-going.